Opportunities in China

At China Focus@BIO Philadelphia, we are going to bring together 100+ Chinese executives from pharma, medical device companies and investment institutions. Some attendees are seeking assets and strategic partners in following categories:

  • Indication: Cancer, kidney disease, autoimmune disease
  • Product type: mAB, protein, peptide, small molecule drugs in phase II or later. 

Contact us if you are interested in exploring potential possibilities in China market.

More Opportunities Available
Our Partnering System is open! Register now and start requesting 1-1 meetings with your best-fit partners to make the most of your trip in Philadelphia.

Register Now

 

Participating Chinese Companies Spotlight

Zhejiang Teruisi Pharmaceutical Co., Ltd. is a CDMO company is dedicated to immunotherapy to treat various types of cancer.

GenFleet Therapeutics Inc. is a China-based R&D biotech company pursuing innovative therapeutic molecules – small and large.

Brii Biosciences is dedicated to serving patients’ needs and improving public health in China. Our mission is to help Chinese patients gain earlier access to more affordable, innovative medicines through partnerships, best-in-class research and development, and the disruptive application of digital and data insight.

Fountain Medical Development K&L is a global contract research organization supporting data management, biostatistics, statistical programming, clinical operations, regulatory affairs, safety, pharmacovigilance, toxicology, medical affairs, medical writing, quality, risk, and compliance services to the pharmaceutical, biotechnology, and medical device industries worldwide.
BioSense was established to address the business needs of the global biopharmaceutical market with a focus on China, Europe, and the U.S. The organization’s mission is to bridge the gap between undercapitalized biopharmaceutical projects, companies, and investors.

Delos Capital is a private equity fund that partners with strong management teams and strategic owners to invest in lower middle market companies.

Shenzhen Share Capital is the venture capital investment team focusing on new drug development, biotechnology, medical device, and medical health.

Northern Light Venture Capital is China-focused venture capital firm targeting early stage opportunities of innovation and disruptive technology.

Register to Schedule 1-1 Meeting with Other Attendees

Innovation Competition

Upcoming Preliminaries: 

  • June 2, Philadelphia (Online Application Deadline: May 22)
    • Partnering opportunities with potential Chinese investors.
    • Exhibition booth for your company at China Focus@BIO Philadelphia with a surprise discount.
    • Media coverage and promotion on our English and Chinese platforms.
    • Opportunity for a 5-day sponsored business development trip in China to meet 100+ investors and corporate executives.
Submit Application Now

Click here to learn more about preliminary schedule and featured prizes.

Partner Event